Abstract
Methods Patients with confirmed first-line therapy failure (d4T or ZDV/3TC/NVP or EFV) as defined virologic (VF), immunologic (IF) and clinical (CF) (according to WHO ARV scale-up guidelines), were eligible. Genotypic drug resistance testing (GRT) was done by viral RNA extraction, RTPCR and in-house sequencing and interpretation done according to the Stanford database. The frequency of DRMs (NNRTI mutations-K103N, V106M, Y181C, G190A and others, 3TC-M184V/I and TAMs: 41, 210, 215 or 67, 70, 219 or no specific pathway) were determined. Univariate analysis were used to determine the risk of development of >3 TAMs according to age, gender, type of failure, duration on regimen, duration of HIV infection, exposure to suboptimal regimens, CD4 counts and PVL at time of GRT.
Highlights
There is limited information on the pattern of drug resistance mutations (DRMs) after failure of NNRTI-based firstline ART in India
We assessed the prevalence of DRMs after first-line failure and explored risk factors associated with development of thymidine analog mutations (TAMs)
Univariate analysis were used to determine the risk of development of >3 TAMs according to age, gender, type of failure, duration on regimen, duration of HIV infection, exposure to suboptimal regimens, CD4 counts and PVL at time of Genotypic drug resistance testing (GRT)
Summary
Address: 1Institute of Infectious Diseases, Pune, India, 2Consultant Biostatistician, Pune, India and 3Genomebio Laboratories, Pune, India * Corresponding author from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 9–13 November 2008. Address: 1Institute of Infectious Diseases, Pune, India, 2Consultant Biostatistician, Pune, India and 3Genomebio Laboratories, Pune, India * Corresponding author from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. Published: 10 November 2008 Journal of the International AIDS Society 2008, 11(Suppl 1):P193 doi:10.1186/1758-2652-11-S1-P193. Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
